Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells

Biochemical Pharmacology

Volumn 70, Issue 5, 2005, Pages 658-667

  Lin, Johnson ^a   Hsiao, Po Wen ^b   Chiu, Ted H ^b   Chao, Jui I ^b  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Celecoxib; Colon cancer; COX 2; Etodolac; Oxalipatin; Survivin

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; INHIBITOR OF APOPTOSIS PROTEIN; OXALIPLATIN; PROSTAGLANDIN E2; SURVIVIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMA CELL; CELL DEATH; CELL DIVISION; CELL GROWTH; CELL SURVIVAL; COLON CANCER; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DRUG SYNERGISM; HUMANS; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; ORGANOPLATINUM COMPOUNDS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 23044508580     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.05.028     Document Type: Article

References (43)

1. D.A. Dixon, N.D. Tolley, P.H. King, L.B. Nabors, T.M. McIntyre, and G.A. Zimmerman Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells J Clin Invest 108 2001 1657 1665
2. J. Brabender, J. Park, R. Metzger, P.M. Schneider, R.V. Lord, and A.H. Holscher Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer Ann Surg 235 2002 440 443
3. S.F. Shariat, J.H. Kim, G.E. Ayala, K. Kho, T.M. Wheeler, and S.P. Lerner Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder J Urol 169 2003 938 942
4. W.S. Chen, J.H. Liu, S.J. Wei, J.M. Liu, C.Y. Hong, and W.K. Yang Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor Cancer Sci 94 2003 253 258
5. A. Tabernero, J.M. Reimund, S. Chasserot, C.D. Muller, and R. Andriantsitohaina Cyclooxygenase-2 expression and role of vasoconstrictor prostanoids in small mesenteric arteries from patients with Crohn's disease Circulation 107 2003 1407 1410
6. W.S. Chen, S.J. Wei, J.M. Liu, M. Hsiao, J. Kou-Lin, and W.K. Yang Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac Int J Cancer 91 2001 894 899
7. C. Han, J. Leng, A.J. Demetris, and T. Wu Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest Cancer Res 64 2004 1369 1376
8. K. Krysan, F.H. Merchant, L. Zhu, M. Dohadwala, J. Luo, and Y. Lin COX-2-dependent stabilization of survivin in non-small cell lung cancer FASEB J 18 2004 206 208
9. K. Krysan, H. Dalwadi, S. Sharma, M. Pold, and S. Dubinett Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer Cancer Res 64 2004 6359 6362
10. J.F. Evans, and S.L. Kargman Cancer and cyclooxygenase-2 (COX-2) inhibition Curr Pharm Des 10 2004 627 634
11. J.J. Keller, and F.M. Giardiello Chemoprevention strategies using NSAIDs and COX-2 inhibitors Cancer Biol Ther 2 2003 S140 S149
12. R.D. Church, J.W. Fleshman, and H.L. McLeod Cyclo-oxygenase 2 inhibition in colorectal cancer therapy Br J Surg 90 2003 1055 1067
13. A.T. Koki, and J.L. Masferrer Celecoxib: a specific COX-2 inhibitor with anticancer properties Cancer Contr 9 2002 28 35
14. F.A. Sinicrope, and S. Gill Role of cyclooxygenase-2 in colorectal cancer Cancer Metastasis Rev 23 2004 63 75
15. K. Kismet, M.T. Akay, O. Abbasoglu, and A. Ercan Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention Cancer Detect Prev 28 2004 127 142
16. J. Marx Angiogenesis. A boost for tumor starvation Science 301 2003 452 454
17. S. Hashitani, M. Urade, N. Nishimura, T. Maeda, K. Takaoka, and K. Noguchi Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines Int J Oncol 23 2003 665 672
18. W.S. Chen, J.H. Liu, J.M. Liu, and J.K. Lin Sequence-dependent effect of a cyclooxygenase-2 inhibitor on topoisomerase I inhibitor and 5-fluorouracil-induced cytotoxicity of colon cancer cells Anticancer Drugs 15 2004 287 294
19. V. Sandor Chronotherapy with 5-fluorouracil, oxaliplatin, and folinic acid in colorectal cancer Lancet 350 1997 1325 1326
20. H. Hochster, A. Chachoua, J. Speyer, J. Escalon, A. Zeleniuch-Jacquotte, and F. Muggia Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer J Clin Oncol 21 2003 2703 2707
21. R.K. Ramanathan, J.W. Clark, N.E. Kemeny, H.J. Lenz, K.O. Gococo, and D.G. Haller Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer J Clin Oncol 21 2003 2904 2911
22. D. Fink, H. Zheng, S. Nebel, P.S. Norris, S. Aebi, and T.P. Lin In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair Cancer Res 57 1997 1841 1845
23. I. Gourdier, M. Del Rio, L. Crabbe, L. Candeil, V. Copois, and M. Ychou Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma FEBS Lett 529 2002 232 236
24. D. Arango, A.J. Wilson, Q. Shi, G.A. Corner, M.J. Aranes, and C. Nicholas Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells Br J Cancer 91 2004 1931 1946
25. D. Pectasides, M. Pectasides, D. Farmakis, A. Gaglia, A. Koumarianou, and M. Nikolaou Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study Gynecol Oncol 95 2004 165 172
26. Q. Ambrosini, C. Adida, and D.C. Altieri A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma Nat Med 3 1997 917 921
27. F. Li, Q. Ambrosini, E.Y. Chu, J. Plescia, S. Tognin, and P.C. Marchisio Control of apoptosis and mitotic spindle checkpoint by survivin Nature 396 1998 580 584
28. J.I. Chao, P.C. Kuo, and T.S. Hsu Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells J Biol Chem 279 2004 20267 20276
29. N.R. Wall, D.S. O'Connor, J. Plescia, Y. Pommier, and D.C. Altieri Suppression of surviving phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis Cancer Res 63 2003 230 235
30. D.S. O'Connor, D. Grossman, J. Plescia, F. Li, H. Zhang, and A. Villa Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin Proc Natl Acad Sci USA 97 2000 13103 13107
31. P.C. Kuo, H.F. Liu, and J.I. Chao Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells J Biol Chem 279 2004 55875 55885
32. K. Kawamura, N. Sato, J. Fukuda, H. Kodama, J. Kumagai, and H. Tanikawa Survivin acts as an antiapoptotic factor during the development of mouse preimplantation embryos Dev Biol 256 2003 331 341
33. A. Chakravarti, G.G. Zhai, M. Zhang, R. Malhotra, D.E. Latham, and M.A. Delaney Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms Oncogene 23 2004 7494 7506
34. B. Lu, Y. Mu, C. Cao, F. Zeng, S. Schneider, and J. Tan Survivin as a therapeutic target for radiation sensitization in lung cancer Cancer Res 64 2004 2840 2845
35. D.C. Altieri The molecular basis and potential role of survivin in cancer diagnosis and therapy Trends Mol Med 7 2001 542 547
36. C. Rodel, J. Haas, A. Groth, G.G. Grabenbauer, R. Sauer, and F. Rodel Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor Int J Radiat Oncol Biol Phys 55 2003 1341 1347
37. M.K. Bhat, C. Yu, N. Yap, Q. Zhan, Y. Hayashi, and P. Seth Tumor suppressor p53 is a negative regulator in thyroid hormone receptor signaling pathways J Biol Chem 272 1997 28989 28993
38. J.A. Plumb, R. Milroy, and S.B. Kaye Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay Cancer Res 49 1989 4435 4440
39. C.E. Eberhart, R.J. Coffey, A. Radhika, F.M. Giardiello, S. Ferrenbach, and R.N. DuBois Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas Gastroenterology 107 1994 1183 1188
40. W.L. Smith, D.L. DeWitt, and R.M. Garavito Cyclooxygenases: structural, cellular, and molecular biology Annu Rev Biochem 69 2000 145 182
41. R. Yamazaki, N. Kusunoki, T. Matsuzaki, S. Hashimoto, and S. Kawai Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells FEBS Lett 531 2002 278 284
42. J. Cheng, H. Imanishi, W. Liu, H. Nakamura, T. Morisaki, and K. Higashino Involvement of cell cycle regulatory proteins and MAP kinase signaling pathway in growth inhibition and cell cycle arrest by a selective cyclooxygenase 2 inhibitor, etodolac, in human hepatocellular carcinoma cell lines Cancer Sci 95 2004 666 673
43. Q.L. Deveraux, and J.C. Reed IAP family proteins - suppressors of apoptosis Genes Dev 13 1999 239 252